News
ALEC
4.960
-5.52%
-0.290
Weekly Report: what happened at ALEC last week (0415-0419)?
Weekly Report · 3d ago
Shareholders in Alector (NASDAQ:ALEC) have lost 75%, as stock drops 12% this past week
Alector, Inc. (NASDAQ:ALEC) has lost 19% in the last week. The share price has fallen 12% per year over the last half decade. Alector saw its revenue increase by 36% in last decade. The company made a loss in the past 12 months. The stock is showing 3 warning signs in our analysis of the company.
Simply Wall St · 04/17 12:02
Weekly Report: what happened at ALEC last week (0408-0412)?
Weekly Report · 04/15 09:16
Weekly Report: what happened at ALEC last week (0401-0405)?
Weekly Report · 04/08 09:18
Weekly Report: what happened at ALEC last week (0325-0329)?
Weekly Report · 04/01 09:17
Weekly Report: what happened at ALEC last week (0318-0322)?
Weekly Report · 03/25 09:17
Alector: Initial statement of beneficial ownership of securities
Press release · 03/21 22:23
Alector Inc Announces Board Retirement and New Members
TipRanks · 03/21 20:12
Weekly Report: what happened at ALEC last week (0311-0315)?
Weekly Report · 03/18 09:17
Weekly Report: what happened at ALEC last week (0304-0308)?
Weekly Report · 03/11 09:17
Have Insiders Sold Alector Shares Recently?
Co-Founder of Alector, Inc. (NASDAQ:ALEC) recently sold US$130k worth of stock at US$6.92 per share. The sale of shares by Arnon Rosenthal amounts to 0.4% of the company's share price. A lector insiders didn't buy any shares over the last year. The company has a 9.5% of shares in the company, but there's been no insider buying in the last three months. It's worth analysing the nature of insider transactions at Alectors.
Simply Wall St · 03/08 10:29
Alector’s Clinical Progress and Financial Health Anchor Buy Recommendation
TipRanks · 03/07 05:06
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
NKGen Biotech stock is rocketing more than 65% alongside heavy pre-market trading. Infobird shares are soaring close to 53% with strong early morning trading. Earnings reports, share offerings and more are the biggest pre- market stock movers this morning.
Investorplace · 03/06 12:23
Weekly Report: what happened at ALEC last week (0226-0301)?
Weekly Report · 03/04 09:17
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results
Alector, Inc. (NASDAQ:ALEC) reported a 6.5% rise in revenues to US$97m in its latest full-year results. Revenues are expected to fall 36% in the year to 2024. The analysts have downgraded their revenue estimates for Alector. The company is expected to perform worse than the wider industry. The consensus price target for the company is US$15.80 per share.
Simply Wall St · 03/01 11:46
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)
TipRanks · 02/29 11:40
Alector Price Target Maintained With a $41.00/Share by HC Wainwright & Co.
Dow Jones · 02/28 17:21
HC Wainwright & Co. Reiterates Buy on Alector, Maintains $41 Price Target
Benzinga · 02/28 17:11
Optimistic Buy Rating for Alector’s AL002 Based on Promising Alzheimer’s Disease Trial Biomarkers and TREM2 Signaling Efficacy
TipRanks · 02/28 12:38
Alector, Inc. (NASDAQ:ALEC) institutional owners may be pleased with recent gains after 20% loss over the past year
Institutional investors own over 50% of Alector, Inc. (NASDAQ:ALEC) The top 7 shareholders own 52% of the company. The company is owned by institutions and the largest shareholders hold around 68% of its shares. The last year has seen a huge increase in the share price of alector. It is worth looking at the company's ownership of shares to see if insiders are buying or selling.
Simply Wall St · 02/28 11:30
More
Webull provides a variety of real-time ALEC stock news. You can receive the latest news about Alector through multiple platforms. This information may help you make smarter investment decisions.
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.